Eggert, Angelika

The landscape of genomic alterations across childhood cancers

ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 1,572

Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation

Sprüssel, A., Schulte, J. H., Weber, S., Necke, M., Händschke, K., Thor, T., Pajtler, K. W., Schramm, A., König, K., Diehl, L., et al. (2012) · Leukemia

Hematopoietic Stem Cell TransplantationAcute Myeloid Leukemia Research

Cited by 203

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget

Neuroblastoma Research and TreatmentsCancer-related Molecular Pathways

Cited by 85

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., et al. (2017) · Cell Death & Disease

Neuroblastoma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 67

Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN -Amplified Cancers

Montuori, G., Tu, F., Qin, D., Schmargon, R., Rodriguez-Fos, E., Helmsauer, K., Hui, H., Mandal, S., Purshouse, K., Fankhänel, L., et al. (2025) · Cancer Discovery

Neuroblastoma Research and TreatmentsGenomic variations and chromosomal abnormalities

Cited by 15